Pfizer (PFE)
23.98
-0.77 (-3.11%)
NYSE · Last Trade: Aug 6th, 12:29 PM EDT
Detailed Quote
Previous Close | 24.75 |
---|---|
Open | 24.68 |
Bid | 23.98 |
Ask | 23.99 |
Day's Range | 23.96 - 24.71 |
52 Week Range | 20.92 - 30.43 |
Volume | 26,318,918 |
Market Cap | 134.45B |
PE Ratio (TTM) | 12.76 |
EPS (TTM) | 1.9 |
Dividend & Yield | 1.720 (7.17%) |
1 Month Average Volume | 44,665,738 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
Trump tweets trigger major stock swings for companies like Tesla, Boeing, Pfizer. Democrats demand an investigation.
Via Benzinga · August 6, 2025
How does $740 in annual income sound?
Via The Motley Fool · August 6, 2025
The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million.
Via Benzinga · August 6, 2025
US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up to 250%. Bond yields down & Fed may cut rates.
Via Benzinga · August 6, 2025
The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.
Via Stocktwits · August 6, 2025
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.
Via Benzinga · August 6, 2025
Via Benzinga · August 6, 2025
A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red.
Via Chartmill · August 6, 2025
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZenecastocktwits.com
Via Stocktwits · August 5, 2025
The large pharmaceutical company reported strong second-quarter earnings results.
Via The Motley Fool · August 5, 2025
Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock into a breakout.
Via Investor's Business Daily · August 5, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.
Via Chartmill · August 5, 2025
Pfizer In Talks With Trump Administration Regarding Lower Drug Prices And Tariffs, Says CEO: Stock Rallies On Improved Full-Year Guidance, Upbeat Q2 Reportstocktwits.com
Via Stocktwits · August 5, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · August 5, 2025
Palantir, Pfizer, Hims & Hers, Intel, UnitedHealth: Stocks Making The Biggest Moves Todaystocktwits.com
Via Stocktwits · August 5, 2025
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc.
Via Benzinga · August 5, 2025
TSMC stock fall on news of suspected trade secrets theft at the semiconductor manufacturing powerhouse, a major player in the AI chip market.
Via Investor's Business Daily · August 5, 2025
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
Via Chartmill · August 5, 2025
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.
Via Chartmill · August 5, 2025
Pfizer's second-quarter 2025 results exceeded expectations with a 10% revenue growth and an adjusted EPS of $0.78.
Via Talk Markets · August 5, 2025
Pfizer posts better-than-expected Q2 earnings and sales, raises 2025 EPS outlook, and outlines $7.7 billion in cost-saving initiatives through 2027.
Via Benzinga · August 5, 2025
Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around $9.53 billion, close to analysts’ estimates. Its non-GAAP profit of $1.76 per share was 9.2% above analysts’ consensus estimates.
Via StockStory · August 5, 2025
Shares advanced within striking distance of their 50-day line.
Via Investor's Business Daily · August 5, 2025
It's been a roller-coaster ride for Pfizer's stock over the past half-decade.
Via The Motley Fool · August 5, 2025